Reuters: IPOX® Associate Muehlbauer Comments on U.S. IPO Resilience

A recent Reuters article discusses the resilience of the U.S. IPO pipeline, noting that a slew of companies across sectors, from biotech to real estate, launched IPO roadshows on Monday. As issuers prepare to go ahead with their listing plans despite recent market swings and geopolitical tensions, the article highlights several key players actively advancing toward the public markets. This wave of new offerings includes biotechs Alamar Biosciences, Inc. and Kailera Therapeutics, convenience store chain Yesway, and hospital REIT National Healthcare Properties.

While the IPO market faced some headwinds in February and March due to volatility linked to AI-disruption fears and the Middle East conflict, analysts suggest that the stage is set for a steady pickup in activity. With Wall Street's fear gauge, the VIX Volatility Index, recently falling below 20, signs of market stability are encouraging the substantial backlog of pre-IPO companies waiting on the sidelines to confidently launch their offerings.

IPOX® Research Associate Lukas Muehlbauer was featured in the piece, providing analysis on the overall trajectory and health of the 2026 IPO landscape. Muehlbauer highlighted that the market's momentum remains robust, emphasizing how current valuation dynamics are creating a favorable environment for newly public companies.

"2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it may even get there without the mega listings. Disciplined pricing and attractive valuations make this a 'buyer's market', giving those deals a stronger chance of trading well after listing."

Read the full article by Arasu Kannagi Basil and Prakhar Srivastava on Reuters: US IPO hopefuls forge ahead with listing plans amid market swings